Stephens Inc Bristol Myers Squibb CO Transaction History

Stephens Inc

$6.77 Billion
Q3 2024

A detailed history of Stephens Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Stephens Inc holds 155,309 shares of BMY stock, worth $8.96 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

155,309

Previous 153,832 0.96%

Holding current value

$8.96 Million

Previous $6.39 Million 25.81%

% of portfolio

0.12%

Previous 0.1%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$39.66 - $51.75 $58,577 - $76,434	1,477 Added 0.96%	155,309 $8.04 Million
Q2 2024 Aug 06, 2024	SELL	$40.25 - $52.99 $403,103 - $530,694	-10,015 Reduced 6.11%	153,832 $6.39 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $2.85 Million - $3.23 Million	59,431 Added 56.92%	163,847 $8.89 Million
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $218,596 - $260,845	-4,509 Reduced 4.14%	104,416 $5.36 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $23,792 - $26,604	-411 Reduced 0.38%	108,925 $6.32 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $121,877 - $135,325	1,913 Added 1.78%	109,336 $6.99 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $3.63 Million - $4.12 Million	-55,235 Reduced 33.96%	107,423 $7.45 Million
Q4 2022 Jan 25, 2023	BUY	$68.48 - $81.09 $2.52 Million - $2.98 Million	36,780 Added 29.22%	162,658 $11.7 Million
Q3 2022 Nov 02, 2022	SELL	$0.13 - $76.84 $2,893 - $1.71 Million	-22,254 Reduced 15.02%	125,878 $8.95 Million
Q2 2022 Aug 03, 2022	SELL	$72.62 - $79.98 $348,648 - $383,983	-4,801 Reduced 3.14%	148,132 $11.4 Million
Q1 2022 May 04, 2022	BUY	$61.48 - $73.72 $75,989 - $91,117	1,236 Added 0.81%	152,933 $11.2 Million
Q4 2021 Mar 07, 2022	SELL	$53.63 - $62.52 $449,902 - $524,480	-8,389 Reduced 5.24%	151,697 $9.46 Million
Q3 2021 Oct 27, 2021	SELL	$59.17 - $69.31 $670,336 - $785,212	-11,329 Reduced 6.61%	160,086 $9.47 Million
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $529,887 - $577,047	8,559 Added 5.26%	171,415 $11.5 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $1.42 Million - $1.6 Million	23,997 Added 17.28%	162,856 $10.3 Million
Q4 2020 Feb 10, 2021	SELL	$57.74 - $65.43 $3.44 Million - $3.9 Million	-59,592 Reduced 30.03%	138,859 $8.61 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $3.2 Million - $3.55 Million	55,743 Added 39.06%	198,451 $12 Million
Q2 2020 Aug 24, 2020	BUY	$54.82 - $64.09 $463,777 - $542,201	8,460 Added 6.3%	142,708 $8.39 Million
Q1 2020 May 14, 2020	SELL	$46.4 - $67.43 $283,504 - $411,997	-6,110 Reduced 4.35%	134,248 $7.48 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $706,557 - $921,640	14,358 Added 11.4%	140,358 $9.01 Million
Q3 2019 Oct 18, 2019	BUY	$42.77 - $50.71 $309,825 - $367,343	7,244 Added 6.1%	126,000 $6.39 Million
Q2 2019 Aug 01, 2019	SELL	$44.62 - $49.34 $4.36 Million - $4.82 Million	-97,776 Reduced 45.16%	118,756 $5.39 Million
Q1 2019 May 03, 2019	BUY	$45.12 - $53.8 $2.29 Million - $2.73 Million	50,798 Added 30.65%	216,532 $10.3 Million
Q4 2018 Feb 11, 2019	SELL	$48.76 - $63.23 $1.33 Million - $1.72 Million	-27,249 Reduced 14.12%	165,734 $8.62 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $304,538 - $343,495	5,518 Added 2.94%	192,983 $12 Million
Q2 2018 Aug 10, 2018	BUY	$50.53 - $62.98 $19,049 - $23,743	377 Added 0.2%	187,465 $10.4 Million
Q1 2018 May 03, 2018	BUY	$59.92 - $68.98 $491,403 - $565,704	8,201 Added 4.58%	187,088 $11.8 Million
Q4 2017 Feb 05, 2018	BUY	$59.94 - $65.35 $249,050 - $271,529	4,155 Added 2.38%	178,887 $11 Million
Q3 2017 Nov 08, 2017	SELL	$55.23 - $63.74 $158,951 - $183,443	-2,878 Reduced 1.62%	174,732 $11.1 Million
Q2 2017 Aug 10, 2017	BUY	N/A	177,610	177,610 $9.9 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account